NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Trial Profile

NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Macular degeneration; Retinal vein occlusion
  • Focus Therapeutic Use
  • Acronyms NEWTON
  • Most Recent Events

    • 07 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 17 Feb 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top